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GIVING-UP SMOKING: PREDICTIVE FACTORS OF SMOKING
CESSATION AND ATTEMPTSTO STOP IN A FRENCH COHORT
Thomas D
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OBJECTIVES: The aim of this analysis was to measure the
smokers’ behaviors with regards to smoking cessation and deter-
mine the attempts to stop and predictive factors of quitting
smoking. METHODS: A representative French national sample
of 6032 subjects aged 15 years or more received a self-
administered questionnaire in November 2006. Subjects identi-
ﬁed as smokers were recontacted in June 2007 in order to
complete a telephone administered questionnaire. Current
smokers were investigated during the two phases on smoking
habits, consumption, quit attempts, predictive factors of quit
attempts. A descriptive analysis was performed for each phase in
order to determine the smokers’ behaviors between the two
phases towards tobacco cessation. RESULTS: The response rate
of the ﬁrst phase was 66% (21% of them were current smokers,
26% ex-smokers and 53% never smoked). Forty percent of
smokers declared intention to stop smoking. Among them 55%
expected to quit smoking within the 2 to 6 next months (22% of
total smokers). The main reason reported for quitting smoking
was the high price of cigarettes (65%), followed by the wish to
improve physical condition (53%). France’s smoking ban, and
information campaigns by the media represented less than 10%.
During the second phase, 521 smokers were interviewed. Twenty
four percent had attempted to stop (11% stopped smoking and
13% attempted and failed to stop smoking between the two
phases). Twenty three percent of quit attempts (successful or
failed) were initiated by a physician. The main reason mentioned
by individuals who stopped or attempted to stop was health
improvement (80%). The expected bans of January 2008 were
mentioned by 17% of individuals who stopped smoking. CON-
CLUSIONS: Health improvement seems to be the main motiva-
tion for smokers to quit. Health care professionals should have a
pivotal role in helping smokers to reach this objective.
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Fifty percent of all smokers will die from a smoking-related
disease such as chronic obstructive pulmonary disease (COPD),
cardiovascular disease (CVD) or lung cancer. Apart from an
obvious cost-effective population strategy preventing initiation of
smoking (primary prevention), the majority of health care
resources are being devoted to tertiary prevention (treatment) of
diseases. Secondary prevention initiatives for smoking cessation
is currently not highly prioritised, although these initiative may
also be cost-effective. OBJECTIVES: To investigate the incremen-
tal cost-effectiveness rates (costs per QALY gained) published for
secondary prevention (smoking cessation) versus tertiary preven-
tion (treatment) of smoking-related diseases (COPD, CVD and
lung cancer). These results are compared to the reimbursement
status in Denmark, Sweden, Norway, Finland, Belgium and The
Netherlands. METHODS: The costs per QALY gained from
different smoking cessation activities as well as the costs per
QALY gained from tertiary prevention (treatment) of COPD,
CVD and lung cancer were reviewed using The Cost-
Effectiveness Analysis Registry (Tufts Medical Center, US) until
2005 and using Medline from 2005–2008. Costs per QALY
gained found were compared with the reimbursement status in
the six countries. RESULTS: Forty-seven ICER-rates (15 studies)
were identiﬁed in smoking cessation ranging from “cost-saving”/
“dominating” and to $34,000/QALY gained (median $1,117,
10%-percentile “cost-saving”, 90%-percentile $9,500). The
median cost per QALY managing smoking-related diseases (182
ICER-rates, 76 studies) were between $22,000–44,000 with the
highest in COPD (10%-percentile “cost-saving”, 90%-percentile
$92,000) and largest dispersion in lung cancer (10%-percentile
“cost-saving”, 90%-percentile $96,709, maximum $2,400,000).
However, this is not reﬂected in governments policies in the six
countries, since cost-effective smoking cessation through pre-
scription medicine is only reimbursed in Sweden (2nd line) and
Belgium. CONCLUSIONS: Using the case of smoking, this study
concludes that secondary prevention (smoking cessation) is as
least as cost-effective as tertiary prevention of smoking-related
diseases. However, this is not reﬂected in all governments’ reim-
bursement policies today.
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OBJECTIVES: The Patient eDiary is an 11 item electronic diary
developed in US English by Boehringer Ingelheim to collect data
for group comparisons of subjects with Chronic Obstructive
Pulmonary Disease (COPD). The Patient eDiary was translated
into 55 languages for utilization in an international study. A
rigorous methodology was required to ensure conceptual equiva-
lence and cultural relevance across languages within the con-
straints of the handheld electronic device via which the
questionnaire is administered. METHODS: The translation
process was conducted by specialists in each target country,
following a standardized methodology: 1) two independent
forward translations by native target language speakers; 2) com-
parison and reconciliation of the translations; 3) back translation
by a native English speaker; 4) comparison of original and back
translation; 5) review by a clinician; and 6) comprehension test
on 5 COPD patients. RESULTS: The major challenge was ﬁnding
conceptually equivalent and culturally relevant formulations
which ﬁtted into the limited space of 79 characters per screen
provided by the handheld device. This was manageable for lan-
guages using the Roman alphabet although the structure of some
require between 10 to 15 % more characters than English to
convey the same notion. The characters of languages using a
different script had to be reduced to 45 per screen given the size
and space they require. A high percentage of abbreviations had to
be used and careful testing was essential to ascertain comprehen-
sion by the target population. Examples of these and other con-
straints will be discussed in the presentation. CONCLUSIONS:
The 55 language versions of the Patient eDiary were established
according to a rigorous methodology to ensure conceptual
equivalence and cultural relevance across languages within the
constraints of the handheld device. The Patient eDiary may now
be used conﬁdently for comparison of results and pooling of data
in international studies involving COPD patients.
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